Detalles de la búsqueda
1.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Ann Oncol
; 34(6): 531-542, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062416
2.
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Curr Med Res Opin
; 32(7): 1217-24, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26971372
Resultados
1 -
2
de 2
1
Próxima >
>>